Pharmacokinetics, Pharmacokinetics, Distribution and Excretion of Empagliflozin, a Sodium-Glucose Co-Transporter (SGLT 2) Inhibitor, in Mice, Rats, and Dogs

The metabolism, pharmacokinetics, excretion and distribution of a sodium-glucose co-transporter (SGLT 2) inhibitor, empagliflozin, were studied in mice, rats and beagle dogs following a single oral or intravenous administration of [14C]-empagliflozin. Empagliflozin was well absorbed in all species after oral administration. The clearance of empagliflozin was low in dog and moderate in mice and rats. Volume of distribution and half-life were generally moderate in all species. Oral bioavailability was moderate in rats (31%) and high in mice (90–97%) and dogs (89%).

For Remaining Article: http://www.annexpublishers.com/full-text/JPDD/3302/Pharmacokinetics-Biotransformation-Distribution-and-Excretion-of-Empagliflozin-a-Sodium-Glucose-Co-Transporter.php